Why Are Traditional Serialization Architectures No Longer Enough
It has been over a decade now since the original Traditional Track & Trace (T&T), serialization architectures were originally developed. These systems were primarily built to comply with regulatory mandates and support compliance-driven data recording, with a high focus on ease of implementation and little focus on interoperability.
As supply chains become more complex, these existing, typically on-premises and/or single-vendor systems lack the scalability, flexibility, real-time data visibility, and data exchange capabilities requiredto manage high-volume, asynchronous, and multi-partner transactions. Moreover, the absence of globally standardized compliance rules makes it difficult for manufacturers, wholesalers, and distributors to adopt a single, efficient, scalable, and interoperable system that meets global product demands.
As a result, organizations are finding that traditional Track & Trace (T&T) serialization architectures for the pharmaceutical industry are no longer sufficient and are increasingly inadequate. As existing systems inevitably require operating systems or other upgrades, there are some important points to consider prior to proceeding.
1. Moving from “Inflexible Data Silos” to “Data Liquidity”
Traditional systems often offer limited data processing options, creating a ‘data graveyard’ by locking information into isolated, local repositories and making it difficult to share with internal systems and external partners, including international supply chains and regulatory bodies.
Legacy architecture was not designed to function as a single, coherent platform, making it difficult to synchronize data between plant-floor and front-office systems.
On the contrary, modern supply chains require “data liquidity,” which is the ability for information to flow seamlessly among manufacturers, CMOs, distributors, and regulators.
2. Achieving Data Interoperability in a Multi-Partner World
Global trade requires a common language. As trade becomes increasingly global and supply chains involve multiple partners, the lack of standardized communication hampers efficient, timely access to data. Traditional systems often require expensive, custom-built bridges to share data with external partners.
Real-time access to traceability data is essential, yet many existing systems are not equipped to provide this level of detail.
Adopting the Open Serialization communication method at the plant level (such as a PLC-based system that can talk to the other systems on the same network in real time – but the traditional Level 2 doesn’t) and EPCIS2.0 may be key to enabling more open, interoperable data across supply chain partners and enterprise systems within the organization.
3. Achieving Scalability and Flexibility
Many serialization platforms in operation today were architected for relatively modest transaction volumes and predictable, synchronous workflows. The reality of modern pharmaceutical operations looks very different.
With a slight change in the existing regulation and as new regulations are enacted in emerging markets, scaling these systems on on-premises infrastructure is rarely straightforward. Infrastructure upgrades often trigger extensive validation efforts, and each functional enhancement risks cascading changes across tightly coupled components. Over time, organizations accumulate layers of customizations and workarounds, creating brittle systems that are expensive to maintain and slow to evolve.
Modern, cloud-native architectures replace this “technical debt” with elasticity, allowing you to scale operations instantly without the fragility of custom-built workarounds.
4. Adapting Systems from Reactive to Predictive
Today’s business requires real-time, end-to-end visibility. The traditional system infrastructure is often focused solely on the recording and reporting of static data. Issues are discovered after they have materialized, rather than being anticipated and mitigated. Serialization remains a cost center rather than evolving into a source of strategic insight.
These systems are not designed to integrate with modern enterprise systems and other data analytics platforms, including AI-driven business intelligence and predictive maintenance applications, which are increasingly integral to industry infrastructure.
The Strategic Shift: Modern architectures integrate with AI-driven analytics and predictive maintenance, turning serialization from a “compliance tax” into a source of actionable business intelligence.
5. Escalating Regulatory Pressure & Operational Complexity
As regulations evolve, compliance is becoming more operationally complex, with increasing emphasis on end-to-end traceability, rapid recall execution, and cross-border data exchange.
Traditional serialization methods struggle to keep pace and often require resource-intensive efforts to maintain the operational system, leading to compliance issues and costly penalties. Legacy setups struggle to accommodate multiple packaging configurations, leading to production downtime and higher unit costs.
An agile architecture doesn’t merely manage complexity; it absorbs it, ensuring that changes in law don’t halt production.
The Bottom Line
In summary, organizations that continue to treat serialization as a narrow compliance function will find themselves constrained by aging architectures precisely when flexibility, visibility, and data-driven decision-making become competitive differentiators.
To remain competitive and quickly adapt to ever-changing regulatory requirements, life sciences companies must adopt more robust, flexible, vendor-agnostic Track & Trace serialization solutions that provide easily accessible data and the visibility and traceability needed to track products across borders.
To advance toward Pharma 4.0, serialization 2.0 is essential, not just a compliance mandate.
